7.1 Effects of Daratumumab on Laboratory Tests 8 USE IN SPECIFIC POPU LATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL …
DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma...
DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell …
DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: • multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed
DARZALEX® (daratumumab) is indicated for the treatment of adult patients with multiple myeloma: • In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: • In combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant
Type and screen patients prior to starting DARZALEX FASPRO. The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase)...
Daratumumab (DARZALEX) | FDA - U.S. Food and Drug Administration
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and...
DARZALEX (Janssen Biotech, Inc.): FDA Package Insert
Oct 31, 2024 · DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
Daratumumab Information from Drugs.com
Oct 14, 2024 · Daratumumab Package Insert or Daratumumab HCP. Review the full Daratumumab Package Insert (Darzalex brand) for more detailed information about this medicine. Discuss any medical questions you have with your doctor or other health care provider.
- Some results have been removed